Vir Biotechnology (VIR) PT Lowered to $59 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VIR Hot Sheet
Price: $11.77 +4.90%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $59.00 (from $61.00) while maintaining a Buy rating.
You May Also Be Interested In
- Vir Biotechnology Inc. (VIR) Tops Q3 EPS by 17c
- Kraft Heinz Company (KHC) PT Raised to $24 at Jefferies
- Stanley Black & Decker (SWK) PT Raised to $135 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
